Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120


Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model.

Ramsey HE, Oganesian A, Gorska AE, Fuller L, Arrate M, Boyd K, Keer H, Azab M, Savona MR.

Target Oncol. 2020 Mar 28. doi: 10.1007/s11523-020-00709-x. [Epub ahead of print]


A Phase 1 Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults With Advanced Cancers or Lymphoma.

Mita MM, LoRusso PM, Papadopoulos KP, Gordon MS, Mita AC, Ferraldeschi R, Keer H, Oganesian A, Su XY, Jueliger S, Tolcher AW.

Clin Cancer Res. 2020 Jan 3. pii: clincanres.1430.2019. doi: 10.1158/1078-0432.CCR-19-1430. [Epub ahead of print]


A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.

Oza AM, Matulonis UA, Alvarez Secord A, Nemunaitis J, Roman LD, Blagden SP, Banerjee S, McGuire WP, Ghamande S, Birrer MJ, Fleming GF, Markham MJ, Hirte HW, Provencher DM, Basu B, Kristeleit R, Armstrong DK, Schwartz B, Braly P, Hall GD, Nephew KP, Jueliger S, Oganesian A, Naim S, Hao Y, Keer H, Azab M, Matei D.

Clin Cancer Res. 2020 Mar 1;26(5):1009-1016. doi: 10.1158/1078-0432.CCR-19-1638. Epub 2019 Dec 12.


Mass balance and metabolite profiling of 14C-guadecitabine in patients with advanced cancer.

Roosendaal J, Rosing H, Lucas L, Gebretensae A, Huitema ADR, van Dongen MG, Beijnen JH, Oganesian A.

Invest New Drugs. 2019 Oct 11. doi: 10.1007/s10637-019-00854-9. [Epub ahead of print]


Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial.

Di Giacomo AM, Covre A, Finotello F, Rieder D, Danielli R, Sigalotti L, Giannarelli D, Petitprez F, Lacroix L, Valente M, Cutaia O, Fazio C, Amato G, Lazzeri A, Monterisi S, Miracco C, Coral S, Anichini A, Bock C, Nemc A, Oganesian A, Lowder J, Azab M, Fridman WH, Sautès-Fridman C, Trajanoski Z, Maio M.

Clin Cancer Res. 2019 Dec 15;25(24):7351-7362. doi: 10.1158/1078-0432.CCR-19-1335. Epub 2019 Sep 17.


Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer.

Slovin S, Hussain S, Saad F, Garcia J, Picus J, Ferraldeschi R, Crespo M, Flohr P, Riisnaes R, Lin C, Keer H, Oganesian A, Workman P, de Bono J.

Clin Cancer Res. 2019 Aug 1;25(15):4624-4633. doi: 10.1158/1078-0432.CCR-18-3212. Epub 2019 May 21.


An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study.

Savona MR, Odenike O, Amrein PC, Steensma DP, DeZern AE, Michaelis LC, Faderl S, Harb W, Kantarjian H, Lowder J, Oganesian A, Azab M, Garcia-Manero G.

Lancet Haematol. 2019 Apr;6(4):e194-e203. doi: 10.1016/S2352-3026(19)30030-4.


Development and validation of LC-MS/MS methods for the quantification of the novel anticancer agent guadecitabine and its active metabolite β‑decitabine in human plasma, whole blood and urine.

Roosendaal J, Wang K, Rosing H, Lucas L, Gebretensae A, Oganesian A, Schellens JHM, Beijnen JH, Lin ZJ.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Mar 1;1109:132-141. doi: 10.1016/j.jchromb.2019.01.011. Epub 2019 Jan 22.


A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to Irinotecan.

Lee V, Wang J, Zahurak M, Gootjes E, Verheul HM, Parkinson R, Kerner Z, Sharma A, Rosner G, De Jesus-Acosta A, Laheru D, Le DT, Oganesian A, Lilly E, Brown T, Jones P, Baylin S, Ahuja N, Azad N.

Clin Cancer Res. 2018 Dec 15;24(24):6160-6167. doi: 10.1158/1078-0432.CCR-18-0421. Epub 2018 Aug 10.


A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses.

Matei D, Ghamande S, Roman L, Alvarez Secord A, Nemunaitis J, Markham MJ, Nephew KP, Jueliger S, Oganesian A, Naim S, Su XY, Keer H, Azab M, Fleming GF.

Clin Cancer Res. 2018 May 15;24(10):2285-2293. doi: 10.1158/1078-0432.CCR-17-3055. Epub 2018 Mar 2.


Simultaneous Modeling of Biomarker and Toxicity Response Predicted Optimal Regimen of Guadecitabine (SGI-110) in Myeloid Malignancies.

Xu C, Goggin TK, Su XY, Taverna P, Oganesian A, Lowder JN, Azab M, Kantarjian H.

CPT Pharmacometrics Syst Pharmacol. 2017 Oct;6(10):712-718. doi: 10.1002/psp4.12248. Epub 2017 Sep 28.


Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.

Wagner AJ, Agulnik M, Heinrich MC, Mahadevan D, Riedel RF, von Mehren M, Trent J, Demetri GD, Corless CL, Yule M, Lyons JF, Oganesian A, Keer H.

Eur J Cancer. 2016 Jul;61:94-101. doi: 10.1016/j.ejca.2016.03.076. Epub 2016 May 5.


Alpha1a-Adrenoceptor Genetic Variant Triggers Vascular Smooth Muscle Cell Hyperproliferation and Agonist Induced Hypertrophy via EGFR Transactivation Pathway.

Gradinaru I, Babaeva E, Schwinn DA, Oganesian A.

PLoS One. 2015 Nov 16;10(11):e0142787. doi: 10.1371/journal.pone.0142787. eCollection 2015.


Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.

Issa JJ, Roboz G, Rizzieri D, Jabbour E, Stock W, O'Connell C, Yee K, Tibes R, Griffiths EA, Walsh K, Daver N, Chung W, Naim S, Taverna P, Oganesian A, Hao Y, Lowder JN, Azab M, Kantarjian H.

Lancet Oncol. 2015 Sep;16(9):1099-1110. doi: 10.1016/S1470-2045(15)00038-8. Epub 2015 Aug 19.


Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors.

Mita M, Gordon M, Rosen L, Kapoor N, Choy G, Redkar S, Taverna P, Oganesian A, Sahai A, Azab M, Bristow R, Tolcher AW.

Cancer Chemother Pharmacol. 2014 Jul;74(1):195-204. doi: 10.1007/s00280-014-2481-1. Epub 2014 May 22.


Alpha1a-adrenoceptor genetic variant induces cardiomyoblast-to-fibroblast-like cell transition via distinct signaling pathways.

Kleine-Brueggeney M, Gradinaru I, Babaeva E, Schwinn DA, Oganesian A.

Cell Signal. 2014 Sep;26(9):1985-97. doi: 10.1016/j.cellsig.2014.05.007. Epub 2014 May 15.


SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome.

Tellez CS, Grimes MJ, Picchi MA, Liu Y, March TH, Reed MD, Oganesian A, Taverna P, Belinsky SA.

Int J Cancer. 2014 Nov 1;135(9):2223-31. doi: 10.1002/ijc.28865. Epub 2014 Apr 5.


A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors.

Tibes R, Fine G, Choy G, Redkar S, Taverna P, Oganesian A, Sahai A, Azab M, Tolcher AW.

Cancer Chemother Pharmacol. 2013 Feb;71(2):463-71. doi: 10.1007/s00280-012-2019-3. Epub 2012 Nov 23.


Genomic Medicine: Why Do "Similar" Patients Have Different Outcomes?

Schwinn D, Kleine-Brueggeney M, Oganesian A.

Rev Course Lect. 2012 May;2012:30-34.


Safety, tolerability, and pharmacokinetics of amuvatinib from three phase 1 clinical studies in healthy volunteers.

Choy G, Joshi-Hangal R, Oganesian A, Fine G, Rasmussen S, Collier J, Kissling J, Sahai A, Azab M, Redkar S.

Cancer Chemother Pharmacol. 2012 Jul;70(1):183-90. doi: 10.1007/s00280-012-1821-2. Epub 2012 Feb 15.


[Endocrine therapy for postmenopausal breast cancer (role of cycline D1)].

Manikhas AG, Skvortsov VA, Manikhas GM, Raskin GA, Oganesian AS, Shemerovskiĭ AK.

Vopr Onkol. 2011;57(5):641-4. Russian. No abstract available.


Constitutive coupling of a naturally occurring human alpha1a-adrenergic receptor genetic variant to EGFR transactivation pathway.

Oganesian A, Yarov-Yarovoy V, Parks WC, Schwinn DA.

Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19796-801. doi: 10.1073/pnas.1116271108. Epub 2011 Nov 16.


[The influence of beta-adrenoblocking therapy on the markers of systemic inflammation in patients with acute coronary syndrome].

Sisakian AS, Davtian AR, Pepoian SK, Oganesian AS.

Klin Med (Mosk). 2011;89(4):56-9. Russian.


Reversible covalent binding of neratinib to human serum albumin in vitro.

Chandrasekaran A, Shen L, Lockhead S, Oganesian A, Wang J, Scatina J.

Drug Metab Lett. 2010 Dec;4(4):220-7.


In vitro metabolism, permeability, and efflux of bazedoxifene in humans.

Shen L, Ahmad S, Park S, DeMaio W, Oganesian A, Hultin T, Scatina J, Bungay P, Chandrasekaran A.

Drug Metab Dispos. 2010 Sep;38(9):1471-9. doi: 10.1124/dmd.109.030999. Epub 2010 Jun 1.


Characterization of HKI-272 covalent binding to human serum albumin.

Wang J, Li-Chan XX, Atherton J, Deng L, Espina R, Yu L, Horwatt P, Ross S, Lockhead S, Ahmad S, Chandrasekaran A, Oganesian A, Scatina J, Mutlib A, Talaat R.

Drug Metab Dispos. 2010 Jul;38(7):1083-93. doi: 10.1124/dmd.110.032292. Epub 2010 Apr 16.


The neurosecretory vesicle protein phogrin functions as a phosphatidylinositol phosphatase to regulate insulin secretion.

Caromile LA, Oganesian A, Coats SA, Seifert RA, Bowen-Pope DF.

J Biol Chem. 2010 Apr 2;285(14):10487-96. doi: 10.1074/jbc.M109.066563. Epub 2010 Jan 22.


Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.

Martone RL, Zhou H, Atchison K, Comery T, Xu JZ, Huang X, Gong X, Jin M, Kreft A, Harrison B, Mayer SC, Aschmies S, Gonzales C, Zaleska MM, Riddell DR, Wagner E, Lu P, Sun SC, Sonnenberg-Reines J, Oganesian A, Adkins K, Leach MW, Clarke DW, Huryn D, Abou-Gharbia M, Magolda R, Bard J, Frick G, Raje S, Forlow SB, Balliet C, Burczynski ME, Reinhart PH, Wan HI, Pangalos MN, Jacobsen JS.

J Pharmacol Exp Ther. 2009 Nov;331(2):598-608. doi: 10.1124/jpet.109.152975. Epub 2009 Aug 11.


Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities.

Oganesian A, Shilling AD, Young-Sciame R, Tran J, Watanyar A, Azam F, Kao J, Leung L.

Psychopharmacol Bull. 2009;42(2):47-63.


(S)-N-(5-Chlorothiophene-2-sulfonyl)-beta,beta-diethylalaninol a Notch-1-sparing gamma-secretase inhibitor.

Cole DC, Stock JR, Kreft AF, Antane M, Aschmies SH, Atchison KP, Casebier DS, Comery TA, Diamantidis G, Ellingboe JW, Harrison BL, Hu Y, Jin M, Kubrak DM, Lu P, Mann CW, Martone RL, Moore WJ, Oganesian A, Riddell DR, Sonnenberg-Reines J, Sun SC, Wagner E, Wang Z, Woller KR, Xu Z, Zhou H, Jacobsen JS.

Bioorg Med Chem Lett. 2009 Feb 1;19(3):926-9. doi: 10.1016/j.bmcl.2008.11.116. Epub 2008 Dec 6.


Discovery of begacestat, a Notch-1-sparing gamma-secretase inhibitor for the treatment of Alzheimer's disease.

Mayer SC, Kreft AF, Harrison B, Abou-Gharbia M, Antane M, Aschmies S, Atchison K, Chlenov M, Cole DC, Comery T, Diamantidis G, Ellingboe J, Fan K, Galante R, Gonzales C, Ho DM, Hoke ME, Hu Y, Huryn D, Jain U, Jin M, Kremer K, Kubrak D, Lin M, Lu P, Magolda R, Martone R, Moore W, Oganesian A, Pangalos MN, Porte A, Reinhart P, Resnick L, Riddell DR, Sonnenberg-Reines J, Stock JR, Sun SC, Wagner E, Wang T, Woller K, Xu Z, Zaleska MM, Zeldis J, Zhang M, Zhou H, Jacobsen JS.

J Med Chem. 2008 Dec 11;51(23):7348-51. doi: 10.1021/jm801252w.


Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade.

Jacobsen JS, Comery TA, Martone RL, Elokdah H, Crandall DL, Oganesian A, Aschmies S, Kirksey Y, Gonzales C, Xu J, Zhou H, Atchison K, Wagner E, Zaleska MM, Das I, Arias RL, Bard J, Riddell D, Gardell SJ, Abou-Gharbia M, Robichaud A, Magolda R, Vlasuk GP, Bjornsson T, Reinhart PH, Pangalos MN.

Proc Natl Acad Sci U S A. 2008 Jun 24;105(25):8754-9. doi: 10.1073/pnas.0710823105. Epub 2008 Jun 16.


Discovery of a novel series of Notch-sparing gamma-secretase inhibitors.

Kreft A, Harrison B, Aschmies S, Atchison K, Casebier D, Cole DC, Diamantidis G, Ellingboe J, Hauze D, Hu Y, Huryn D, Jin M, Kubrak D, Lu P, Lundquist J, Mann C, Martone R, Moore W, Oganesian A, Porte A, Riddell DR, Sonnenberg-Reines J, Stock JR, Sun SC, Wagner E, Woller K, Xu Z, Zhou H, Steven Jacobsen J.

Bioorg Med Chem Lett. 2008 Jul 15;18(14):4232-6. doi: 10.1016/j.bmcl.2008.05.064. Epub 2008 May 20.


[Intensive care and anesthetic maintenance in intra-abdominal hypertension].

Mkhoian GG, Akopian RV, Oganesian AK.

Anesteziol Reanimatol. 2007 Sep-Oct;(5):40-6. Review. Russian.


Thrombospondins use the VLDL receptor and a nonapoptotic pathway to inhibit cell division in microvascular endothelial cells.

Oganesian A, Armstrong LC, Migliorini MM, Strickland DK, Bornstein P.

Mol Biol Cell. 2008 Feb;19(2):563-71. Epub 2007 Nov 21.


The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease.

Riddell DR, Zhou H, Comery TA, Kouranova E, Lo CF, Warwick HK, Ring RH, Kirksey Y, Aschmies S, Xu J, Kubek K, Hirst WD, Gonzales C, Chen Y, Murphy E, Leonard S, Vasylyev D, Oganesian A, Martone RL, Pangalos MN, Reinhart PH, Jacobsen JS.

Mol Cell Neurosci. 2007 Apr;34(4):621-8. Epub 2007 Jan 25.


[The influence of some elicitors on growth and morphogenesis of Hypericum perforatum callus cultures].

Vardapetian GR, Oganesian AA, Kabasakalian EE, Tiratsuian SG.

Ontogenez. 2006 Nov-Dec;37(6):419-23. Russian.


The NH2-terminal propeptide of type I procollagen acts intracellularly to modulate cell function.

Oganesian A, Au S, Horst JA, Holzhausen LC, Macy AJ, Pace JM, Bornstein P.

J Biol Chem. 2006 Dec 15;281(50):38507-18. Epub 2006 Oct 3.


[On the occasion of the 20th anniversary of the accident on the Chernobyl NPP: medical consequences in Armenia].

Oganesian NM, Petrosian ShM, Miridzhanian MI, Asrian KV, Pogosian AS, Oganesian AN, Abramian AK, Arutiunian GR, Karapetian AG, Gevorkian EG, Petrosian ZhG, Arutiunian NK.

Radiats Biol Radioecol. 2006 May-Jun;46(3):341-7. Russian.


[Role of mosquitoes in the transmisson of arboviruses in Armenia].

Manukian DV, Oganesian AS, Shakhnazarian SA, Aleksanian IuT.

Med Parazitol (Mosk). 2006 Apr-Jun;(2):38-9. Russian. No abstract available.


[The species composition of mosquitoes and ticks in Armenia].

Manukian DV, Oganesian AS, Shakhnazarian SA, Aleksanian IuT.

Med Parazitol (Mosk). 2006 Jan-Mar;(1):31-3. Russian.


[Treatment of a burn stricture of the esophagus complicated with a fistula].

Chernousov AF, Chernookov AI, Chernousov FA, Oganesian AV.

Khirurgiia (Mosk). 2005;(4):4-8. Russian.


A receptor-like inositol lipid phosphatase is required for the maturation of developing cochlear hair bundles.

Goodyear RJ, Legan PK, Wright MB, Marcotti W, Oganesian A, Coats SA, Booth CJ, Kros CJ, Seifert RA, Bowen-Pope DF, Richardson GP.

J Neurosci. 2003 Oct 8;23(27):9208-19.


PTPRQ is a novel phosphatidylinositol phosphatase that can be expressed as a cytoplasmic protein or as a subcellularly localized receptor-like protein.

Seifert RA, Coats SA, Oganesian A, Wright MB, Dishmon M, Booth CJ, Johnson RJ, Alpers CE, Bowen-Pope DF.

Exp Cell Res. 2003 Jul 15;287(2):374-86.


Protein tyrosine phosphatase RQ is a phosphatidylinositol phosphatase that can regulate cell survival and proliferation.

Oganesian A, Poot M, Daum G, Coats SA, Wright MB, Seifert RA, Bowen-Pope DF.

Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7563-8. Epub 2003 Jun 11.


The rainbow trout (Oncorhynchus mykiss) tumor model: recent applications in low-dose exposures to tumor initiators and promoters.

William DE, Bailey GS, Reddy A, Hendricks JD, Oganesian A, Orner GA, Pereira CB, Swenberg JA.

Toxicol Pathol. 2003 Jan-Feb;31 Suppl:58-61. Review.


Retraction. Neutrophil elastase mutations in severe congenital neutropenia patients of the original Kostmann family.

Aprikyan AA, Carlsson G, Stein S, Oganesian A, Fadeel B, Dale DC, Palmblad J, Henter JI.

Blood. 2004 Jan 15;103(2):389. Epub 2003 Jan 16. No abstract available.


[Circulation of tick-borne encephalitis virus in Armenia].

Oganesian AS.

Zh Mikrobiol Epidemiol Immunobiol. 2002 Jan-Feb;(1):107-8. Russian. No abstract available.


Supplemental Content

Loading ...
Support Center